Acticor Biotech
Acticor Biotech is a Paris-based, clinical-stage biopharmaceutical company developing glenzocimab, a single proprietary drug candidate for the treatment of acute ischemic stroke, sustained pre-revenue by repeated private capital raises and awaiting further financing and regulatory milestones.
- Company typePrivate
- Founded2010
- HeadquartersParis, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Acticor Biotech firmographics
Firmographics- Name
- Acticor Biotech
- Legal name
- Acticor Biotech
- Website
- https://acticor-biotech.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Acticor Biotech is a Paris-based, clinical-stage biopharmaceutical company developing glenzocimab, a single proprietary drug candidate for the treatment of acute ischemic stroke, sustained pre-revenue by repeated private capital raises and awaiting further financing and regulatory milestones.
- Ownership category
- akta.pro rank
Acticor Biotech industry classification
Industry- Product category
- Acute Stroke Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industry
- Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)
Keywords
Where Acticor Biotech is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Markets served
Acticor Biotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Drug Development and Commercialization: Pre-revenue biopharmaceutical company developing glenzocimab for stroke treatment. Revenue generation expected through future drug commercialization or licensing agreements upon regulatory approval.
Acticor Biotech product offering
Product offeringCore offering
Acticor Biotech is developing glenzocimab, a clinical-stage monoclonal antibody fragment drug candidate for the acute-phase treatment of acute ischemic stroke. The company operates as a clinical-stage biopharmaceutical R&D organization pursuing regulatory validation of a single proprietary asset targeting an underserved therapeutic area.
Differentiator
Problem solved
Functional benefit
Products and services
- Glenzocimab
Companies that use Acticor Biotech
Customer profileSegments1 record
Ideal customer profiles1 record
Acticor Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Acticor Biotech partnerships and signals
Strategic signalScale indicators2 records
Acticor Biotech competitors and assessment
Company assessmentEmerging players
- Athersys: Developed MultiStem cell therapy for ischemic stroke (MASTERS-2 program); directly comparable clinical-stage biotech targeting the same acute ischemic stroke population.
- ZZ Biotech: Clinical-stage biotech developing 3K3A-APC for acute ischemic stroke; directly comparable single-asset, neuro-protection-oriented developer focused on the same indication.
- ReNeuron Group: Developed CTX cell therapy for stroke disability; comparable UK-listed clinical-stage biotech addressing post-stroke neurology outcomes.
- DiaMedica Therapeutics: Developing DM199 (klotho-based biologic) for acute ischemic stroke; emerging clinical-stage peer with overlapping neurovascular therapeutic development.
- Noxxon Pharma: European clinical-stage biotech developing Spiegelmer-based biologics; comparable small-cap, single-asset European biotech with similar pre-revenue clinical profile.
Broad incumbents
- Ablynx (Sanofi): Developer of caplacizumab (nanobody/antibody-fragment) for acquired TTP; Sanofi's nano-body franchise represents the closest antibody-fragment platform comparable to glenzocimab.
- Boehringer Ingelheim: Markets Actilyse (alteplase) and has developed tenecteplase for acute ischemic stroke; large incumbent with overlapping stroke-treatment indication and post-stroke biologics expertise.
- Biogen: Large neurology-focused biopharmaceutical incumbent with biologics expertise across neurovascular/neurodegenerative indications; comparable strategic-acquirer profile for late-stage stroke assets.
- Genentech (Roche): Developer of Activase (alteplase), the established intravenous thrombolytic standard of care for acute ischemic stroke; broad incumbent neurology/biologics portfolio with overlapping indication.
Direct peers
- Annexon, Inc. Clinical-stage complement-inhibitor biotech whose mechanism-based neurovascular approach is conceptually analogous to glenzocimab's targeted biological intervention; serves as a directly comparable emerging player.
Market position
Customer concentration
Acticor Biotech social profiles
Digital presenceActicor Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Acticor Biotech leadership team
Management profileNumber of profiles
Profiles5 records
Acticor Biotech funding detail
Funding detailFunding overview
Funding rounds9 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Acticor Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Acticor Biotech
What does Acticor Biotech do?
Acticor Biotech is developing glenzocimab, a clinical-stage monoclonal antibody fragment drug candidate for the acute-phase treatment of acute ischemic stroke. The company operates as a clinical-stage biopharmaceutical R&D organization pursuing regulatory validation of a single proprietary asset targeting an underserved therapeutic area.
Is Acticor Biotech a public or private company?
Acticor Biotech is a private company. It is classified as venture growth investor backed and is currently operating.
When was Acticor Biotech founded?
Acticor Biotech was founded in 2010. It employs 11 to 50 people.
Where is Acticor Biotech based?
Acticor Biotech is headquartered in Paris, France, in the Europe region.
How does Acticor Biotech make money?
One revenue line is on record: drug Development and Commercialization.
Who are Acticor Biotech's main competitors?
Emerging players on record are Athersys, ZZ Biotech, ReNeuron Group, DiaMedica Therapeutics and Noxxon Pharma. Broad incumbents are Ablynx (Sanofi), Boehringer Ingelheim, Biogen and Genentech (Roche). Annexon, Inc. is listed as a direct peer.
Does Acticor Biotech have an API?
No public API is recorded for Acticor Biotech.
What industry is Acticor Biotech in?
Acticor Biotech's product category is Acute Stroke Therapeutics. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.